Literature DB >> 27983735

Dyslipidaemia: Predicting the benefits and risks of PCSK9 inhibition.

David Holmes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27983735     DOI： 10.1038/nrendo.2016.215

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Authors:  Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.